GFM
KROS icon

GF Fund Management’s Keros Therapeutics KROS Stock Holding History

GF Fund Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.75K Sell
631
-46
-7% -$512 ﹤0.01% 558
2026
Q1 		$7.47K Buy
677
+79
+13% +$1.22K ﹤0.01% 582
2025
Q4 		$12.2K Sell
598
-272
-31% -$4.77K ﹤0.01% 561
2025
Q3 		$13.8K Sell
870
-166
-16% -$2.45K ﹤0.01% 529
2025
Q2 		$13.8K Hold
1,036
– – ﹤0.01% 535
2025
Q1 		$10.6K Buy
1,036
+192
+23% +$2.23K ﹤0.01% 558
2024
Q4 		$13.4K Buy
+844
New +$43.9K ﹤0.01% 511

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

GF Fund Management's KROS Position: Q2 2026 in Review

GF Fund Management reduced its Keros Therapeutics (KROS) stake by 6.8% in Q2 2026, selling an estimated $512 and leaving 631 shares worth $6.75K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

GF Fund Management first reported a position in KROS in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.8K in Q2 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • GF Fund Management held 631 shares of Keros Therapeutics worth $6.75K as of Q2 2026.
  • GF Fund Management sold 46 Keros Therapeutics shares in Q2 2026, an estimated $512.
  • Keros Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #558 holding.
  • GF Fund Management first reported a position in Keros Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Keros Therapeutics position peaked at $13.8K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.